| Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile B Paiva, T Paino, JM Sayagues, M Garayoa, L San-Segundo, M Martín, ... Blood, The Journal of the American Society of Hematology 122 (22), 3591-3598, 2013 | 174 | 2013 |
| Tumor resistance against ALK targeted therapy-where it comes from and where it goes GG Sharma, I Mota, L Mologni, E Patrucco, C Gambacorti-Passerini, ... Cancers 10 (3), 62, 2018 | 87 | 2018 |
| Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential T Paíno, B Paiva, JM Sayagués, I Mota, T Carvalheiro, LA Corchete, ... Leukemia 29 (5), 1186-1194, 2015 | 86 | 2015 |
| Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma M Menotti, C Ambrogio, TC Cheong, C Pighi, I Mota, SH Cassel, ... Nature medicine 25 (1), 130-140, 2019 | 68 | 2019 |
| Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma E Karaca Atabay, C Mecca, Q Wang, C Ambrogio, I Mota, N Prokoph, ... Blood, The Journal of the American Society of Hematology 139 (5), 717-731, 2022 | 25 | 2022 |
| Identification of a characteristic copy number alteration profile by high‐resolution single nucleotide polymorphism arrays associated with metastatic sporadic colorectal cancer M González‐González, C Fontanillo, MM Abad, ML Gutiérrez, I Mota, ... Cancer 120 (13), 1948-1959, 2014 | 19 | 2014 |
| ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer I Mota, E Patrucco, C Mastini, NR Mahadevan, TC Thai, E Bergaggio, ... Nature Cancer 4 (7), 1016-1035, 2023 | 11 | 2023 |
| ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK. CAR-T cells E Bergaggio, WT Tai, A Aroldi, C Mecca, E Landoni, M Nüesch, I Mota, ... Cancer cell 41 (12), 2100-2116. e10, 2023 | 10 | 2023 |
| Comment on “ALK is a therapeutic target for lethal sepsis” RB Blasco, E Patrucco, I Mota, WT Tai, R Chiarle Science translational medicine 10 (471), eaar4321, 2018 | 8 | 2018 |
| Altered interphase fluorescence in situ hybridization profiles of chromosomes 4, 8q24, and 9q34 in pancreatic ductal adenocarcinoma are associated with a poorer patient outcome ML Gutiérrez, L Muñoz-Bellvis, ME Sarasquete, DG Hernández-Mejía, ... The Journal of Molecular Diagnostics 16 (6), 648-659, 2014 | 3 | 2014 |
| Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma C Mastini, M Campisi, E Patrucco, G Mura, A Ferreira, C Costa, ... Science Translational Medicine 15 (702), eabo3826, 2023 | 2 | 2023 |
| Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load PP Nanaware, ZN Khan, CC Clement, M Shetty, I Mota, ES Seltzer, ... Cell Reports 43 (6), 2024 | | 2024 |
| 1509-F TFEB activation in mediastinal lymph nodes: a potential modulator of immune response in NSCLC I Mota, L Santambrogio Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | | 2023 |
| 1147-G ERV-derived peptides as novel immunotherapeutic targets in ovarian cancer I Mota, L Santambrogio Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023 | | 2023 |
| Characterization of the HLA-F ligandome in T-cell lymphoma IF Mota, J Osean, E Song, CC Clement, J Lenz, DE Miller, G Inghirami, ... The Journal of Immunology 210 (1_Supplement), 222.06-222.06, 2023 | | 2023 |
| In vitro model of ALK+ Anaplastic Large cells lymphoma and vascular interactions and prediction of drug efficacy in a 3D microfluidic chip M Campisi, C Voena, I Mota, E Patrucco, RD Kamm, V Chiono, R Chiarle CANCERTO-NANOSCIENCE IN CANCER IMMUNOTHERAPY, 52, 2023 | | 2023 |
| 317 ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density E Bergaggio, WT Tai, A Aroldi, E Landoni, M Nuesch, I Mota, J Metovic, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 264 SIRPa blockade synergizes with radiation therapy in murine breast cancer models M Charpentier, C Lhuillier, I Mota, S Trombetta, S Demaria Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| Phenotypic identification of subclones in multiple myeloma with different genomic profile, clonogenic potential and drug sensitivity T Paíno, B Paiva, JM Sayagués, I Mota, T Carvalheiro, LA Corchete, ... Blood, The Journal of the American Society of Hematology 122 (21), 531-531, 2013 | | 2013 |
